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Potential of nanoscale triazine based dendritic macromolecules G1, G2 and G3 as solubility
enhancers of drug was investigated. Effect of pH, concentration and generation of syn-
thesized dendritic macromolecules on solubility of ketoprofen was studied. G3 dendrimer
was further exploited as carrier for sustained release. Ketoprofen was encapsulated by
inclusion complex method and also characterized by Flourier Transform Infrared spec-
troscopy. Sustained release study of ketoprofen from ketoprofen loaded dendrimer was
carried out and compared with free ketoprofen. Hemolytic potential and Cytotoxicity assay
using A-549 lung cancer cell lines revealed that synthesized triazine based dendritic
macromolecules having more potential that commercially available PAMAM dendrimer.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of
the most widely prescribed medications in the world. Their
main benefit originates from their anti-inflammatory and
analgesic properties [1]. These drugs are commonly employedDepartment, V.P. & R.P.T
om, zhhundds@163.com
g Pharmaceutical Univer
University. Production an
ns.org/licenses/by-nc-ndfor the conditions associated with osteoarthritis and other
chronic musculoskeletal conditions [2,3]. Ketoprofen is a
member of nonsteroidal anti-inflammatory drug, also used as
an inhibitor of prostaglandin synthetase [4], administered
orally, three or four times per day [5]. Several side effects are
related with ketoprofen such as gastrointestinal side effects,
renal side effects and additional side effects such as.P. Science College, Affiliated to Sardar Patel University, Vallabh
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the use of ketoprofen in the parenteral application could
control these critical side effects. However, low water solubi-
lity of ketoprofen leads to poor bioavailability pose a great
challenge for the formulation of drug [7] for use in topical and
parenteral applications. Many methodologies have been
applied to improve solubility and reduce side effects of keto-
profen for example use of liposomes, synthetic polymer as
drug delivery agents [8,9]. Ketoprofen has often employed as
model drug for such studies [10].
Dendrimers are three dimensional, nanosized macromol-
ecules having monodisperse molecular weight distribution
obtained by repetitive sequence of reactions [11]. Dendrimer
have several unique properties such as nano-scale mono-
dispersity, scaffolding properties, amplifiable and function-
able surface groups and dimensions that mimics
biomolecules such as protein [12]. Therefore dendrimers are
often used in biomedical applications such as drug solubili-
zation [13], drug delivery [14], MRI contrast agents [15] etc.
Application of dendrimer as a vehicle for drug delivery has
been of great interest [16].
Dendrimers based on triazine are well known. Synthesis of
triazine dendrimer is facile since it does not require functional
groupmanipulations compared to other classes of dendrimers
such as PAMAM dendrimer [17]. Recently, dendrimers based
on triazine have been used in a wide range of applications
such as in optics [18,19], for the delivery of anti-tumor agents
[20], in molecular recognition [21], catalytic supports [22] etc.
Previously, synthesis and characterization and application
of s-triazine based dendrimer for water remediation has been
reported [23e25]. Synthesized dendrimer has hydroxyl groups
on periphery and previously it has been reported that hy-
droxyl terminated dendrimers are less cytotoxic than amine
terminated PAMAM dendrimers [26] and recent biomedical
applications on triazine based dendrimers [26e28] motivating
us to investigate triazine based dendrimer as a carrier of
sustained release using ketoprofen as a model drug.
In the present investigation, potential of triazine based
dendrimer as potential drug carrier of ketoprofen was evalu-
ated. Ketoprofen was loaded to G3 dendrimer by inclusion
complex method. Ketoprofen loaded dendrimer was further
investigated by Infrared spectroscopy. Release of Ketoprofen
from Ketoprofen-dendrimer complex in dialysis bag was
measured and compared with that of free Ketoprofen. Cyto-
toxicity and hemolysis was carried out to evaluate toxicity and
biocompatibility of the dendrimer.2. Materials and methods
2.1. Materials
Ketoprofen was generously provided by A.R. College of Phar-
macy, Vallabh Vidhyanagar as gift sample. Triazine tri-
chloride (cyanuric chloride), 1,4-butanediamine, acetone,
dichloromethane and methanol were purchased from Sigma-
Aldrich (India) Ltd. All the reagents and solvents for the syn-
thesis and analysis were used as received. Absorbance was
measured on Shimadzu UV-1800 spectrophotometer. Double
distilled water was used for solubility studies. FTIR wascarried out in the range of 250e4000 cm1 using Perkin Elmer-
Spectrum RX-FTIR spectrometer instrument. Carl Ziess-
Primovert inverted microscope was used for microscopic im-
ages of A-549 cell lines.
2.2. Synthesis and characterization of triazine based
dendrimer
Triazine based dendrimer was synthesized by following
method. Triazine trichloride (0.02mmol) was reactedwith 1,4-
butanediamine (0.01 mmol) at 0e5 C to give N,N'-bis(4,6-
dichloro-1,3,5-triazin-2-yl)butane-1,4-diamine as core for
dendrimer synthesis. N,N'-bis(4,6-dichloro-1,3,5-triazin-2-yl)
butane-1,4-diamine was purified by washing with Acetone
and Methanol. N,N'-bis(4,6-dichloro-1,3,5-triazin-2-yl)butane-
1,4-diamine (0.01 mmol) was reacted with diethanolamine
(0.04 mmol) to give hydroxyl terminated generation 1 (G1)
dendrimer. G1 dendrimer was purified by washing and
dispersing in dichloromethane. Similar to first step, G1 den-
drimer (0.01 mmol) was reacted with triazine trichloride
(0.08 mmol) at 0e5 C to give chlorine terminated half gener-
ation G1.5 dendrimer (G1.5). Similar to second step, chlorine
terminated half generation dendrimer (G1.5) (0.01 mmol) was
reacted with diethanolamine (0.16 mmol) to give full genera-
tion hydroxyl terminated dendrimer (G2) [23]. The above two
steps were repeated to give half generation G2.5 and full
generation G3 dendrimers respectively. Synthesized core and
all dendrimer generationswere fully characterized by spectral
analysis such as FT-IR, 1H-NMR, 13C-NMR and ESI-Mass
Spectrometry [23].
2.3. Solubility study
Solubility study was carried out according to the method
described by Higuchi and Connors (1965). Excess of ketoprofen
was added to screw-capped vials containing different con-
centrations (0.6 mmole3 mmol) of dendrimer generations in
buffers of 4.0, 7.4 and 10 pH. Vials were shaken for 48 h at 37 C
in shaking water bath. The vials were centrifuged to remove
undissolved ketoprofen and absorbance of ketoprofen were
measured at its characteristic wavelength 260 nm using Shi-
madzu UV-1800 spectrophotometer.
2.4. Drug encapsulation
Drug loading was performed by reported methods with little
modifications [26,29]. Known amount of ketoprofen was
added to a solution containing G3 dendrimer (3 mmol in 10 ml
of distilled water). The mixture was stirred for 72 h at room
temperature. The mixture was then filtered and 5 ml of
methanol was passed through five times through the filter to
remove excess of ketoprofen. Excess Ketoprofen from filter
and each fraction of methanol was analyzed by UV spectro-
photometer to determine amount of encapsulated drug
indirectly.
2.5. In vitro drug release
Pure ketoprofen was dissolved in methanol (2 mg/ml) and
used as control. The prepared ketoprofen loaded dendrimer
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(the same concentration of ketoprofen as 2 mg/ml pure drug
solution). This solution (2 ml in volume) was transferred to a
dialysis bag (MW cut off ¼ 3000 Da) immediately. The dialysis
bag was placed in a 50 ml-beaker containing 40 ml distilled
water. The outer phase was stirred continuously. After a
scheduled interval of time for 0.5 h, 100 ml of sample was
withdrawn from the outer phase, and the outer phase was
again replenished with 100 ml distilled water. The absorbance
of the outer phase was monitored at 260 nm using aFig. 1 e Structure of A) G1 dendrimer,spectrophotometer in order to characterize the concentration
of ketoprofen.
2.6. Hemolysis study [30]
About 5 ml of the human blood from healthy individual was
collected in a tube containing heparin. The blood was centri-
fuged at 1500 rpm for 3 min. The supernatant (Erythrocyte)
was collected and plasma was discarded. The pellet was
washed for 3 times using 0.75% NaCl and centrifuged atB) G2 dendrimer, C) G3 dendrimer.
Table 1 e Physical description of dendrimer generations.
Compound Molecular formula Appearance Solubility in water Surface groups (number)
G0.5 C10H10Cl4N8 White solid Insoluble Cl (4)
G1 C26H50N12O8 Brown liquid Soluble OH (8)
G1.5 C50H42Cl16N36O8 White solid Insoluble Cl(16)
G2 C114H202N52O40 Brown liquid Soluble OH(32)
G2.5 C210H170N148O40Cl64 White solid Insoluble Cl(64)
G3 C466H810N212O168 Brown liquid Soluble OH(128)
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saline to 0.5%. Washed erythrocytes were stored at 4 C and
used within 6 h for the hemolysis assay. To 0.5 ml of cell
suspension, 0.5 ml of different concentration of test sample
(40, 60, 80 and 100 mg/mL in phosphate buffer saline (pH 7.2))Fig. 2 e Effect of the generations A) G1 dendrimer, B) G2 dendri
Ketoprofen (n ¼ 3).was added and incubated for 1 h. After centrifugation, su-
pernatants were taken and diluted with an equal volume of
normal saline and absorbance was measured at 540 nm. The
phosphate buffer saline and distilled water was used as
minimal and maximum hemolytic control.mer, C) G3 dendrimer and pH on aqueous solubilization of
Fig. 3 e A) IR spectrum of G3(OH)128 dendrimer, B) FT-IR
spectrum of ketoprofen and C) FT-IR spectrum of
ketoprofen loaded G3(OH)128 dendrimer.
Fig. 5 e %Hemolysis of red blood cells by G3 dendrimer
after 1 h of incubation (n ¼ 3).
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The monolayer cell culture was trypsinized and the cell count
was adjusted to 3 lac cells/ml using medium containing 10%
fetal bovine serum. Pre incubate cells at a concentration of
1 106 cells/ml in culturemedium for 3 h at 37 C and 5% CO2.
The cells were seeded at a concentration of 5  104 cells/well
in 100 ml culture medium and incubated at 37 C in 5% CO2
incubator for 24 h. After 24 h, when themonolayer formed, the
supernatant was flicked off and added previously diluted with
media of 100 ml of different concentrations of test extract in
microtitre plates and kept for incubation at 37 C in 5% CO2
incubator for 48 h and cells were periodically checked forFig. 4 e % Cumulative release profile ketoprofen from free ketgranularity, shrinkage, swelling. After 48 h, the sample solu-
tion in the wells was flicked off and 10 ml of MTT dye was
added to each well. The plates were gently shaken and incu-
bated for 4 h at 37 C in 5% CO2 incubator. The supernatant
was removed and 100 ml of DMSO was added and the plates
were gently shaken to solubilize the formed formazan. The
absorbance was measured using a microplate reader at
570 nm.
2.8. Statistical analysis
Data are expressed as the mean standard deviation (SD) of
obtained results. The statistical analysis of data was per-
formed using analysis of variance (ANOVA) (Graphpad,
Version 2.01, San Diego, CA). A value of p < 0.05 was consid-
ered as statistically significant.3. Results and discussion
3.1. Preparation mechanism
Synthesis and characterization of s-triazine based dendritic
generation G1(OH)8 b) G2(OH)32 and G3(OH)128 [Fig. 1] based on
1,4-butanediamine was already reported [23]. As shown in
Table 1, only full generation dendrimers G1(OH)8, G2(OH)32oprofen and ketoprofen containing G3 dendrimer (n ¼ 3).
Fig. 6 e Cytotoxicity of G3 dendrimer on A-549 cell lines
after 48 h of incubation (n ¼ 3).
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dendrimers and core compound were water insoluble.
Therefore, only full generation dendrimers G1(OH)8, G2(OH)32
and G3(OH)128 were utilized for drug solubilization and drug
delivery.
3.2. Drug solubilization
As Shown in Fig. 2 a series of solubility experiments for
ketoprofen by dendrimer generation were carried out using
different concentrations (0.6 mmole3 mmol) of dendrimerFig. 7 e Microscopic images of A-549 cell lines treated with A) C
G3(OH)128 Dendrimer and D) 1000 mg/ml of G3 Dendrimer.generations at pH 4.0, 7.4 and 10.0. Solubility results are fur-
nished in Fig. 2. It was witnessed that dendrimer generation
significantly enhances solubility of practically insoluble drug
ketoprofen in the range of 0.77e4.89 mg/ml by dendrimer
generations. It was also revealed that with an increase in
concentration of dendrimer, solubility of ketoprofen was
increased in a linear manner. It was proposed that as den-
drimer contains a hydrophobic triazine ring in interior regions
which may impart hydrophobic interaction and the hydroxyl
groups in the exterior, which may impart hydrogen bonding
so, thus mechanism could be either hydrophilic interaction or
hydrogen bonding or both [26,27]. It was also observed that
with increased in pH and generation number of dendrimer,
solubility of ketoprofen was increased. With the increase in
generation number, surface area and terminal hydroxyl
groups of dendrimer was increased hence solubility of den-
drimer was increased.3.3. Drug loading and in vitro release
Ketoprofen loaded dendrimer was prepared as per reported
method [26] which was further characterized by UV/Vis
spectrophotometer. It was observed that 24.55% of ketoprofen
was encapsulated in dendrimer. Ketoprofen loaded dendrimer
was further investigated by infrared spectroscopy. As Shown
in Fig. 3A, FT-IR spectrum of pure G3 dendrimer showedontrol; B) 10 mg/ml of G3(OH)128 Dendrimer; C) 100 mg/ml of
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groups, 1068 cm1 for CeO stretching of ether linkages. FT-IR
spectrum of ketoprofen showed absorption bands at
3010 cm1, 2895 cm1 for aliphatic CeH stretching, 1665,
1735 cm1 for carbonyl stretching showed in Fig. 3B. FT-IR
spectrum of ketoprofen loaded G3-dendrimer showed ab-
sorption band at 3410 cm1 for OeH stretching, at 2885,
2810 cm1 for CeH stretching, at 1785, 1615 cm1 for carbonyl
stretching and at 1055 cm1 for CeO stretching showed in
Fig. 3C. So, overall characteristic bands for both G3 dendrimer
and ketoprofen remained unchanged in IR spectrum of keto-
profen loaded dendrimer. So it can be understood that den-
drimer contains hydrophobic triazine ring in interior regions
which may impart hydrophobic interaction and the hydroxyl
groups in the exterior, which may impart hydrogen bonding
so, dendrimer may have enhanced solubility of ketoprofen
and their encapsulation by either hydrophilic interaction or
hydrogen bonding or both [26].
The in vitro drug release of Ketoprofen from ketoprofen
loaded dendrimer was examined in distilled water at room
temperature showed in Fig. 4. 95% of Ketoprofen was released
within 2.5 h from free ketoprofen. Whereas same quantity of
drug was released after 7 h from ketoprofen loaded den-
drimers. So, Ketoprofen loaded dendrimer releases ketoprofen
slowly compared to free ketoprofen.
3.4. Hemolytic potential
It was observed that G3 dendrimer showed Fig. 5 concentra-
tion dependent hemolysis. However, triazine based G3 den-
drimer were significantly less hemolysis compared to PAMAM
dendrimer [31]. Positively charged amine groups of PAMAM
dendrimer interacts with negatively charged surfaces of red
blood cells and caused hemolysis [32]. In comparison, G3
dendrimers have anionic hydroxyl groups on the surface
which minimized interaction with red blood cells and dis-
played significantly less toxicity.
3.5. Cytotoxicity
Cytotoxicity [Fig. 6] displayed that G3 dendrimer displayed
more that 90% cell viability at concentration levels ranging
from 10 mg/ml to 1000 mg/ml. So, G3 dendrimer was signif-
icantly less cytotoxic. Microscopic images showed Fig. 7. A-
D, morphology of A-549 cell lines on when treated with
control and different concentration of dendrimers is dis-
played, which showed a decrease in cell density with in-
crease in dendrimer concentration from 10 mg/ml to
1000 mg/ml [33].4. Conclusion
Dendrimer generations have improved aqueous solubility of
practically insoluble drug ketoprofen. Ketoprofen was
released gradually from ketoprofen loaded dendrimer
compared to free ketoprofen. Cytotoxicity and hemolytic
assay exhibited that the dendrimer was significantly less
toxicity and biocompatible which displayed utility of den-
drimer as potential drug carrier system.Acknowledgments
The authors are grateful to Dr. Bhavesh Patel, The Principal, V.
P. & R.P.T.P. Science College, Vallabh Vidhyanagar, for
providing laboratory facility. Authors are also thankful to
UGC, New Delhi (39/686 2010 (SR)) for providing funds for the
research work. Authors are especially thankful to Dr. Vishnu
A. Patel, A. R. College of Pharmacy, Vallabh Vidhyanagar for
generously providing technical support. Dr. Akshaya Gupte, N.
V. Patel College of Pure and Applied Sciences and SAIF, Punjab
University for spectrophotometric analysis.r e f e r e n c e s
[1] Sostres C, Gargallo CJ, Arroyo MT, et al. Adverse effects of
non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and
coxibs) on upper gastrointestinal tract. Best Pract Res Clin
Gastroenterology 2010;24:121e132.
[2] Marie RG. Epidemiology of nonsteroidal anti-inflammatory
drug-associated gastrointestinal injury. Am J Med
1998;104:23S.
[3] Timothy AC. Nonsteroidal anti-inflammatory drugs,
apoptosis, and colon-cancer chemoprevention. Lancet Oncol
2002;3:166e174.
[4] Yalcin T, Gulgun Y, Umit G. Inclusion of Ketoprofen with
skimmed milk by freeze-drying. Farmaco 1999;54:648e652.
[5] Cho YJ, Choi HK. Enhancement of percutaneous absorption
of ketoprofen: effect of vehicles and adhesive matrix. Int J
Pharm 1998;169:95e104.
[6] Gabriel SE, Jaakkimainnen RL, Bombarier C. Risk for serious
gastrointestinal complications related to use of
nonsteroidal anti-inflammatory drugs. Ann Intern Med
1991;115:787e796.
[7] Polisson R. Nonsteroidal anti-inflammatory drugs: practical
and theoretical considerations in their selection. Am J Med
1996;100:31Se6S.
[8] Maestrelli F, Gonzalez-Rodrı´guez ML, Rabasco AM, et al.
Preparation and characterization of liposomes encapsulating
ketoprofen-cyclodextrin complex for transdermal delivery
method. Int J Pharm 2005;198:55e67.
[9] Shah PP, Desai PR, Singh M. Effect of oleic acid modified
polymeric bilayered nanoparticles on percutaneous delivery
of spantide II and ketoprofen. J Control Rel 2012;158:336e345.
[10] Claudia V, Marlies W, Ju¨rgen H. Evaluation of novel soya-
lecithin formulations for dermal use containing ketoprofen
as a model drug. J Control Release 2000;63:165e173.
[11] Patel H, Patel PM. Dendrimer applications a review. Int J
Pharma Bio Sci 2013;4:454e463.
[12] Tomalia DA. Birth of a new macromolecular architecture:
dendrimers as quantized building blocks for nanoscale
synthetic organic chemistry. Aldrichim Acta 2004;37:39e57.
[13] Gupta U, Agashe HB, Asthana A, et al. Dendrimers: novel
polymeric architectures for solubility enhancement.
Biomacromol 2006;7:649e658.
[14] Mei L, Zhang Z, Zhao L, et al. Pharmaceutical
nanotechnology for oral delivery of anticancer drugs. Adv
Drug Deliv Rev 2013;65:880e890.
[15] Kim KS, Park W, Hu J, et al. A cancer-recognizable MRI
contrast agents using pH-responsive polymeric micelle.
Biomaterials 2014;35:337e343.
[16] Na M, Yiyun C, Tongwen X, et al. Dendrimers as potential
drug carriers. Part II. Prolonged delivery of ketoprofen by
in vitro and in vivo studies. Eur J Med Chem 2006;41:670e674.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 0 6e3 1 3 313[17] Steffensen MB, Hollink E, Kuschel F, et al. Dendrimers based
on [1, 3, 5]-triazines. J Polym Sci A Polym Chem
2006;44:3411e3433.
[18] Rothmann MM, Haneder S, Da Como E, et al. Donor-
substituted 1,3,5-Triazines as host materials for blue
phosphorescent organic light-emitting diodes. Chem Mater
2010;22:2403e2410.
[19] Maiti SK, Jardim MG, Rodrigues J, et al. Organomettalics
2013;32:406e414.
[20] Shukla R, Thomas TP, Peters JL, et al. HER2 specific tumor
targeting with dendrimer conjugated anti-HER2 mAb.
Bioconjugate Chem 2006;17:1109e1115.
[21] Zhang W, Simanek EE. Synthesis and characterization of
higher generation dendrons based on melamine using p-
aminobenzylamine. Evidence for molecular recognition of
Cu(II). Tetrahedron Lett 2001;42:5355e5357.
[22] Chan-Thaw CE, Villa A, Katekomol P, et al. Covalent triazine
framework as catalytic support for liquid phase reaction.
Nano Lett 2010;10:537e541.
[23] Patel R, Gajjar D, Patel H, et al. Facile synthesis,
characterization and properties of triazine based dendrimer.
Int J Chem Sci 2014;12:353e365.
[24] Gajjar D, Patel R, Patel H, et al. Removal of heavy metal ions
from water by hydroxyl terminated triazine-based
dendrimer. Desalin Water Treat 2014. http://dx.doi.org/
10.1080/19443994.2014.922446. Published ahead of the print.
[25] Gajjar D, Patel R, Patel H, et al. Designing of triazine based
dendrimer and its application in removal of heavy metal ions
from water. Chem Sci Trans 2014;3:897e908.[26] Bansal K, Kakde D, Gupta U, et al. Development,
characterization and triazine based dendrimers for delivery
of antitumor agent. J Nanosci Nanotechnol
2010;10:8395e8404.
[27] Patel R, Patel H, Gajjar D, et al. Enhanced solubility of non-
steroidal anti-inflammatory drugs by hydroxyl terminated s-
triazine based dendrimers. Asian J Pharm Clin Res
2014;7:156e161.
[28] Patel HN, Patel RM, Gajjar D, et al. s-Triazine based
dendrimer mediated solubilisation of ketoprofen, ibuprofen
and diflunisal. Int J Pharm Res 2014;6:42e51.
[29] Kolhe P, Misra E, Kannan RM, et al. Drug complexation,
in vitro release and cellular entry of dendrimers and
hyperbranched polymers. Int J Pharm 2003;259:143e160.
[30] Jain S, Kaur A, Puri R, et al. Poly propyl ether imine (PETIM)
dendrimer: a novel non-toxic dendrimer for sustained drug
delivery. Eur J Med Chem 2010;45:4997e5005.
[31] Duncan R, Izzo L. Dendrimer biocompatibility and toxicity.
Adv Drug Deliv Rev 2005;57:2215e2237.
[32] Domanski DM, Klajnert B, Bryszewska M. Influence of
PAMAM dendrimers on human red blood cells.
Bioelectrochem 2004;63:189e191.
[33] Shao N, Su Y, Hu J, et al. Comparison of generation 3
polyamidoamine dendrimer and generation 4
polypropylenimine dendrimer on drug loading, complex
structure, release behavior, and cytotoxicity. Int J Nanomed
2011;6:3361e3372.
